Nimbus handed some of the proceeds of the Gilead and Takeda deals to its investors and used the rest to fund research. The approach contrasts with that typically followed by most biotech startups which are often built for initial public offerings or acquisitions down the road. It appears to have resonated with investors at a time when startups are having difficulty raising money